Equities Analysts Issue Forecasts for AGIO FY2028 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Research analysts at HC Wainwright dropped their FY2028 earnings per share estimates for Agios Pharmaceuticals in a research report issued on Monday, July 13th. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings of ($4.69) per share for the year, down from their previous estimate of ($4.65). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.32) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ FY2029 earnings at ($3.11) EPS and FY2030 earnings at ($0.25) EPS.

Several other equities analysts also recently issued reports on the stock. Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. The Goldman Sachs Group boosted their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 1st. Truist Financial increased their price objective on Agios Pharmaceuticals from $36.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Bank of America raised their target price on Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. cut their target price on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a report on Thursday, June 11th. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Agios Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $42.56.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $38.72 on Wednesday. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00. The company has a market cap of $2.30 billion, a PE ratio of -5.34 and a beta of 0.54. The firm’s 50 day simple moving average is $32.78 and its 200 day simple moving average is $30.25.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.81) by $0.12. The company had revenue of $20.75 million during the quarter, compared to the consensus estimate of $13.30 million. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The company’s quarterly revenue was up 137.7% compared to the same quarter last year.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Creative Planning raised its holdings in shares of Agios Pharmaceuticals by 2.2% during the third quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 280 shares during the period. Assetmark Inc. grew its stake in shares of Agios Pharmaceuticals by 37.9% in the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 362 shares during the period. The Manufacturers Life Insurance Company increased its position in Agios Pharmaceuticals by 0.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock valued at $4,393,000 after buying an additional 512 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Agios Pharmaceuticals by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 588 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its position in Agios Pharmaceuticals by 3.4% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock valued at $796,000 after buying an additional 662 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.